HCMSG - Hepatitis C Mentor & Support Group, Inc.
Search
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
  • Resources
    • Corona Virus
    • Hep C Facts & Stats
    • Medications and Treatments >
      • Patient Assistance Programs
    • Reading
    • Links
  • Programs/Training
    • The Circle Model >
      • THE CIRCLE Registration
      • Group and Facilitator Guide
    • Hepatitis C Online Training
    • The Hepatitis C Education and Support Group Assistance Program
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
    • Holiday 2020
  • Contact Us

Prices for the miracle drugs that cure Hepatitis C are collapsing

2/6/2015

0 Comments

 

By Max Nisen 

February 5, 2015

When California based Gilead Sciences announced a breakthrough treatment in late 2013 that cures most kinds of Hepatitis C, people were outraged at the cost: $84,000 in total, or nearly $1,000 a pill.

There are more expensive drugs, but Gilead Science’s hepatitis drugs’—Sovaldi and Harvoni—combination of eye-popping price, sales, and patient population (100 million plus worldwide) is unprecedented (paywall).

But on February 3rd, Gilead announced in its quarterly earnings call that it expects to cut the price of its Hepatitis C drugs an average of 46% this year in the US. That’s double last year’s discount. Some government plans will pay less than half the list price for Harvoni (a Gilead follow up treatment that combines Sovaldi’s active ingredient with another drug).

 

And the reason why can be summed up in one word: Competition.

Illinois based AbbVie launched a competing drug, known as Viekira Pak, late last year sparking a heated price war as the two companies fight to sign exclusive deals with the middlemen that buy the drugs. Few people pay sticker price for expensive prescription drugs. They’re usually bought through a contract by their insurer, or a government health plan. Drug companies give discounts to convince these plans to prefer their drug over another, exclude a competitor, or to offer it to more of their patients.

As shocking as list prices are, they’re usually only a starting point.

The sheer size of the market and price of the drugs mean negotiations are extremely intense. Sovaldi and Harvoni combined nearly outsold the best-selling drug in the world last year which was AbbVie’s anti-arthritis drug, Humira.

One analyst called the size of the price cuts a “shock” (paywall). Gilead’s stock is down more than 7%, AbbVie’s only slightly less, and the entire biotechnology sector took a hit.

This is a big deal, for more than just investors.

Cheaper prices mean more patients will get these drugs. Many plans restricted access to only very sick patients because it was so expensive. Now more people will get a cheaper cure, an earlier one, and will suffer fewer side effects, which is one of the prime benefits of the drug. That’s a very good thing, though it might not feel that way to shareholders.

 

 

http://qz.com/338840/prices-for-the-miracle-drugs-that-cure-hepatitis-c-are-collapsing/

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy